MedPath

Efficacy and Safety of Antimicrobial Durations Treatment of Infections Associated With Osteosynthesis Material

Phase 3
Recruiting
Conditions
Infections
Interventions
Combination Product: Short course of antibiotherapy
Combination Product: Long course of antibiotherapy
Registration Number
NCT05294796
Lead Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Brief Summary

Infections associated with osteosynthesis material are among the most feared and challenging complications of trauma surgery and can lead to total function loss or limb amputation when complete recovery is to be expected without infection.

This is a clinical trial with the purpose of evaluate the optimal duration of antibiotic therapy in Infections Associated With Osteosynthesis Material Implanted when implant is retained.

Detailed Description

Orthopedic implants for fracture fixation or osteosynthesis material are used for internal fixation of fractures, allowing their stability and consolidation.

Infection associated with osteosynthesis material is one of the most feared and challenging complications of trauma surgery and can lead to total loss of function or amputation of the limb, when complete recovery is to be expected without infection. Furthermore, they involve excessive consumption of antimicrobials, with inadequate prescriptions and prolonged durations that favour superinfections by multidrug-resistant microorganisms, in addition to the drug-related toxicities, especially diarrhea due to Clostridium difficile. Most studies and recommendations on the management of orthopedic implant-associated infections have focused on prosthetic joint infections, and while they share similarities with Infections Associated With Osteosynthesis Material Implanted, there are major differences in terms of risk factors, diagnosis, treatment, and prevention. While the extrapolation of knowledge from prosthetic joint infections to the field of Infections Associated With Osteosynthesis Material Implanted has helped orthopedic surgeons and internists/infectologists in their management, there are large gaps and unanswered questions that represent a new challenge for research in this field. One of these challenges, and focusing on the field of infection treatment, is the search for the best surgical procedure according to the age of the implant and fracture healing, to determine the duration of antibiotic treatment and whether it should be maintained until fracture healing, and which is the most appropriate treatment in each of the scenarios.

The identification of conditions in which the duration of the antimicrobial treatment can be shortened, and in case of prolonged treatments, which antimicrobial has the best safety profile and less impact on the induction of bacterial resistances is of special interest, due to the frequent appearance of toxicities and the increase of bacterial resistances and superinfections by multidrug-resistant bacteria.

If the hypothesis of non-inferiority of short vs. long antibiotic treatments is demonstrated, and the efficacy of antibiotics with less ecological impact in long treatments, the impact on reduction of bacterial resistance, toxicity and health costs will be observed. The project also aims to promote quality and multidisciplinary care, homogenising clinical practice in the management of Infections Associated With Osteosynthesis Material Implanted based on scientific knowledge. Early and personalised patient care with Infections Associated With Osteosynthesis Material Implanted allows for faster recovery, both clinically and functionally, enabling earlier mobility recovery.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
364
Inclusion Criteria
  • Age greater than or equal to 14 years.
  • Stable fracture, even if unconsolidated.
  • Controlled infection (absence of signs or symptoms of sepsis).
  • Early or delayed infection.
  • Availability of antibiotics active against the isolated microorganism.
  • Absence of bone exposure. Patients who initially had bone exposure but during the debridement surgery bone coverage was performed by any method (skin approximation, grafting, vacuum therapy) can be included in the criteria.
  • Signed written informed consent.
  • If there is a possibility of pregnancy (in women of childbearing potential) or paternity, agree to use a highly effective method of birth control recommended by the Clinical Trial Facilitation Group (CTFG) during the treatment phase of the trial
Read More
Exclusion Criteria
  • Late infections
  • Infections of osteosynthesis material in non-long bones.
  • Infections of revision osteosynthesis material or occurring after previous surgeries.
  • Patients who are not expected to be followed up for at least 1 year after completion of antibiotic treatment.
  • Pregnant or lactating women.
  • Patients in whom there may be drug interactions or contraindications described in the technical data sheets of the investigational drugs used in this trial.
  • Infections due to mycobacteria, fungi and parasites (since they are infections that are treated with drugs and for different durations).
  • Patients in whom all the material is replaced during the debridement at the same surgical time (since these patients require antibiotic treatment for less than 8 weeks in all cases).
  • Infections of external fixators.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Short course of antibiotherapyShort course of antibiotherapyPatients enrolled in this arm, will receive 8 weeks of antibiotherapy in case of early infection (\< 2 week), and 12 weeks of antibiotherapy in case of delayed infection (2-10 weeks)
Long course of antibiotherapyLong course of antibiotherapyPatients enrolled in this arm, will receive 12 weeks of antibiotherapy in case of early infection (\< 2 week), and until fracture healing of antibiotherapy in case of delayed infection
Primary Outcome Measures
NameTimeMethod
Number of participants with clinical cure in the test of cure12 months after completion of antimicrobial treatment

A success at the test of cure is the resolution of infection symptoms, the absence of clinical signs and symptoms of infection (persistence of symptoms of infection, relapse of infection after a period without symptoms, or superinfection by a different microorganism) without antibiotic therapy and with C-reactive protein \<10 mg/L (unless another cause justifies a higher C-reactive protein value); If the patient dies, when the death was not related to the infection; and no need for chronic suppressive antibiotic therapy to "control" of the infection.

Radiological healing in the test of cure12 months after completion of antimicrobial treatment

Radiological healing is defined as the presence of radiological signs of fracture consolidation (plain radiographic or CT) of the infected bone. Non-union or absence of consolidation of a fractured bone is defined when it has not completely healed within 9 months after osteosynthesis surgery or when it has not shown progression towards fracture callus formation in 3 consecutive months on serial radiographs.

The REBORNE fracture healing scale will be used for a more accurate assessment of fracture healing on radiographs, or CT if necessary.

Definitive soft tissue coverage at test of cure12 months after completion of antimicrobial treatment

Number of patients who present definitive soft tissue coverage at test of cure

Secondary Outcome Measures
NameTimeMethod
Performance of an antibiogram to assess the development of antimicrobial resistance8 months and 12 months

Standard microbiological techniques will be used to identify microorganisms recovered and to determine antimicrobial susceptibility according to EUCAST recommendation (EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, Version 2.0, 2017) https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf

Surgical wound culture to assess the development of secondary infections8 months and 12 months

To evaluate the appearance of secondary infections during antibiotic treatment that standard microbiological techniques will be used to identify microorganisms recovered and to determine antimicrobial susceptibility according to EUCAST recommendation (EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, Version 2.0, 2017) https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf

Evaluate the need for new surgeries, such as debridement, removal of material, coverage or amputation, through radiological evaluation of fracture union.Day 28, week 8, week 12, month 6 and month 12.

To evaluate the need for new surgeries through radiological evaluation

Evaluation of the functional status, defined as the recovery of the functionality of the limb prior to the fracture, by completing the Quick Disabilities of Arm, Shoulder and Hand questionnaire.6 months and 12 months (visit 6 and 7)

The functional state, normal or reduced, will be evaluated with respect to the situation prior to the fracture. Lower extremity mobility is classified as: walks unassisted; with 1 cane; with 2 canes; with walker; "wander home alone"; not wandering..

Efficacy of each group of antibiotics12 months from the start of antibiotic treatment

Number of days of antibiotic administration

Evaluation the consumption of health resourcesMonth 12

Total number and posology of all the antibiotics that have been administered to the patient will be taken into account, in addition to the new surgeries, new microbiological cultures and hospitalizations that have been required.

Evaluate the number of patients who have required any of the bone or soft tissue reconstruction strategies.Month 12

Total number of new surgeries for better bone or soft tissue coverage: number of vacuum therapies (VAC or PICO), total number of grafts or flaps needed by the patient throughout the study.

Presentation of adverse events (frequency and severity).Through study completion (12 months)

Number of adverse events (frequency and severity) that have happened during the study.

Clostridium difficile infectionDuring treatment or 30 days after completion

Number of cases observed during antibiotic treatment or 30 days after completion.

Recurrence rate8 months and 12 months

To evaluate the recurrence rate during antibiotic treatment.

Trial Locations

Locations (29)

Hospital Universitario Germans Trias i Pujol

🇪🇸

Badalona, Barcelona, Spain

Hospital Universitario Parc Taulí

🇪🇸

Sabadell, Barcelona, Spain

Hospital Universitario Marqués de Valdecilla

🇪🇸

Santander, Cantabria, Spain

Hospital Universitario Jerez de la Frontera

🇪🇸

Jerez De La Frontera, Cádiz, Spain

Hospital San Pedro

🇪🇸

Logroño, La Rioja, Spain

Hospital Universitario Son Espases

🇪🇸

Palma, Illes Balears, Spain

Hospital Universitario El Bierzo

🇪🇸

Ponferrada, León, Spain

Hospital Universitario Príncipe de Asturias

🇪🇸

Alcalá De Henares, Madrid, Spain

Hospital Universitario Virgen del Rocío

🇪🇸

Sevilla, Seville, Spain

Hospital Universitario de Cruces

🇪🇸

Barakaldo, Vizcaya, Spain

Hospital Clínico Universitario Virgen de la Arrixaca

🇪🇸

El Palmar, Murcia, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

Hospital Universitario Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Universitario Clinic de Barcelona

🇪🇸

Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

Hospital Universitario Virgen de las Nieves

🇪🇸

Granada, Spain

Hospital Universitario Puerto Real

🇪🇸

Cádiz, Spain

Hospital Universitari de Bellvitge

🇪🇸

Barcelona, Spain

Hospital Universitario Lucus Augusti

🇪🇸

Lugo, Spain

Hospital Regional Universitario de Málaga

🇪🇸

Málaga, Spain

Hospital Universitario Virgen de la Victoria

🇪🇸

Málaga, Spain

Hospital Universitario Costa del Sol

🇪🇸

Málaga, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Hospital Universitario Virgen de Valme

🇪🇸

Sevilla, Spain

Hospital Universitario Virgen Macarena

🇪🇸

Seville, Spain

Hospital Clínico Universitario Lozano Blesa

🇪🇸

Zaragoza, Spain

Hospital Universitario Ramón y Cajal

🇪🇸

Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath